ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/mRNA-personalised-cancer-vaccine
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/mRNA-personalised-cancer-vaccine
11
trial(s) found.
NCT06623422
Curative
Phase 3
Recruiting
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (
V940-009
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - One Clinical Research
NCT06534983
Curative
Phase 2
Recruiting
A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma (
IMCODE004
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Urothelial carcinoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06305767
Curative
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005) (
V940-005
)
anti-NECTIN4 antibody-drug conjugate
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Bladder cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06077760
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (
INTerpath-002
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05533697
Advanced
Phase 1 / Phase 2
Recruiting
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (
mRNA-4359-P101
)
mRNA personalised cancer vaccine,IDO/PD-L1-targeting
Solid tumour
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2228 - Miranda - Southside Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT03897881
Curative
Phase 2
Recruiting
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942) (
mRNA-4157-P201
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Affinity Clinical Research
NCT03313778
Curative
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (
KEYNOTE-603
)
mRNA personalised cancer vaccine
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - One Clinical Research
NCT06307431
Curative
Phase 2
Active not recruiting
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (
INTerpath-004
).
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06295809
Curative
Phase 2 / Phase 3
Active not recruiting
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007). (
V940-007
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Carcinoma
Skin cancer
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05933577
Curative
Phase 3
Active not recruiting
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001) (
V940-001
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05198752
Advanced
Phase 1
Unknown
A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours (
SWP1001-06
)
mRNA personalised cancer vaccine
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4217 - Benowa - Pindara Private Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Active not recruiting (3)
Unknown (1)
Recruitment Country and State
WA (9)
NSW (8)
VIC (8)
QLD (6)
NZ (4)
SA (2)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (2)
Phase 2 (3)
Phase 2 / Phase 3 (1)
Phase 3 (3)
Trial Type
Curative (9)
Advanced (2)
Cancer Therapy Class
PD-1
91%
PD-1/PD-L1
91%
NECTIN4
9%
IDO
9%
PD-L1
9%
Facility
6009 - Nedlands - One Clinical Research (7)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (4)
2109 - North Ryde - Macquarie University Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4215 - Southport - Tasman Oncology (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
6150 - Murdoch - Affinity Clinical Research (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3199 - Frankston - PASO Medical (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
4215 - Southport - Gold Coast University Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Melanoma
Urothelial carcinoma
Bladder cancer
Clear cell renal cell carcinoma
Kidney cancer
Carcinoma
Skin cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy